MAPT and early-onset autosomal dominant Alzheimer disease: As indicated in Table 1 and clinical trials, multi-target drugs containing an N-benzyl piperazine fragment have shown enhanced efficacy in mitigating cognitive decline and addressing key Alzheimer’s disease pathologies, including amyloid and tau accumulation.